A cost-utility analysis of thrombopoietin receptor agonists for treating pediatric immune thrombocytopenia purpura after failure of first-line therapies.

Du, Huimin; Wang, Jiamin; Livingston, Joel; Alrajhi, Ziyad; Kirby-Allen, Melanie; Chan, Brian; Hancock-Howard, Rebecca; Coyte, Peter C

Du, Huimin; Wang, Jiamin; Livingston, Joel; Alrajhi, Ziyad; Kirby-Allen, Melanie; Chan, Brian; Hancock-Howard, Rebecca; Coyte, Peter C.

Afiliación

Du H; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Wang J; Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Livingston J; NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan, Shandong, China.
Alrajhi Z; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Kirby-Allen M; Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Chan B; NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan, Shandong, China.
Hancock-Howard R; Department of Pediatrics, University of Toronto and The Hospital for Sick Children, Toronto, Ontario, Canada.
Coyte PC; Department of Pediatrics, University of Alberta and Stollery Children's Hospital, Edmonton, Alberta, Canada.

Pediatr Blood Cancer ; : e30523, 2023 Jun 30.

Article en En | MEDLINE | ID: mdl-37391862

Palabras clave

cost-utility analysis; immune thrombocytopenic purpura; thrombopoietin receptor agonists

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google